BioWorld

Feb. 6, 2007

Regeneron's Antibody Platform Draws $120M In First License

Regeneron Pharmaceuticals Inc. unveiled the first licensing deal for what it believes is a revolutionary antibody discovery technology, a nonexclusive agreement with a guarantee of $80 million. (Bioworld Today) Read More

Deal-Making Competition Is Up; Winners Offer More Than Money

Researchers Share Strategies To Avoid Getting Lost In Translation

Bush Proposes To Up FDA Budget In Next Fiscal Year

Wyeth's Pair Of Hemophilia Deals Target Longer Action

Columbia Labs Plunges On Prochieve Phase III Failure

Enzo Brings In $15M For Various Clinical Programs

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Feb. 3, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...